1. Oral smoothened inhibitors for Gorlin syndrome: A clinical review.
- Author
-
Baczynski A, Cahn B, Worley B, Haber R, and Alam M
- Subjects
- Humans, Administration, Oral, Anilides administration & dosage, Anilides adverse effects, Anilides therapeutic use, Treatment Outcome, Male, Female, Antineoplastic Agents adverse effects, Antineoplastic Agents administration & dosage, Quinazolines administration & dosage, Quinazolines therapeutic use, Quinazolines adverse effects, Biphenyl Compounds administration & dosage, Drug Administration Schedule, Benzimidazoles, Phenylurea Compounds, Basal Cell Nevus Syndrome drug therapy, Smoothened Receptor antagonists & inhibitors, Skin Neoplasms drug therapy, Pyridines administration & dosage, Pyridines adverse effects, Pyridines therapeutic use
- Abstract
Although smoothened inhibitors (SMOi) have demonstrated efficacy in the management of basal cell carcinoma, no guidelines are available on how to utilize SMOi in the treatment of Gorlin syndrome (GS). This review's objective is to assess the clinical response to SMOi in GS, provide practical guidance for clinicians, and identify areas for future research. Through comprehensive searches of previous publications and expert opinion, this review demonstrates that intermittent dosing of SMOi and daily dosing have similar efficacy. While the adverse events of SMOi may result in their discontinuation during treatment of GS, intermittent dosing may improve compliance., Competing Interests: Conflicts of interest None disclosed., (Copyright © 2024 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF